Parkinson’s disease (PD) is one of the common progressive neurodegenerative disorders with several motor and non-motor symptoms. Most of the motor symptoms may appear at a late stage where most of the dopaminergic neurons have been already damaged. In order to provide better clinical intervention and treatment at the onset of disease, it is imperative to find accurate biomarkers for early diagnosis, including prodromal diagnosis and preclinical diagnosis. At the same time, these reliable biomarkers can also be utilized to monitor the progress of the disease. In this review article, we will discuss recent advances in the development of PD biomarkers from different aspects, including clinical, biochemical, neuroimaging and genetic aspects. Al...
Marina Picillo,1 Marcello Moccia,2 Emanuele Spina,2 Paolo Barone,1 Maria Teresa Pellecchia1 1Departm...
Background: Patients with Parkinson’s disease (PD) have variable rates of progression. More accurate...
BackgroundParkinson’s disease (PD) is the second‐most common neurodegenerative disorder after Alzhei...
Parkinson's disease (PD) is a neurodegenerative disorder whose aetiology remains unclear: degenerati...
Parkinson\u27s disease (PD) is a highly prevalent and irreversible neurodegenerative disorder that i...
Biomarkers are characteristics that can be measured as an indicator of a normal biological process, ...
Parkinson's disease is a common multisystem neurodegenerative disorder characterized by typical moto...
Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the co...
Background: Using surrogate biomarkers for disease progression as endpoints in neuroprotective clin...
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selecti...
Parkinson’s Disease (PD) is the most prevalent neurodegenerative disease following Alzheimer’s disea...
Parkinson’s disease (PD) is a progressive neurodegenerative disorder caused mainly by lack of dopami...
Parkinson’s disease (PD) is a common, heterogeneous syndrome diagnosed clinically by the presence of...
peer-reviewedParkinson’s disease (PD) is the second-leading cause of dementia and is characterized b...
The need for an early and differential diagnosis of Parkinson's disease (PD) is undoubtedly one of t...
Marina Picillo,1 Marcello Moccia,2 Emanuele Spina,2 Paolo Barone,1 Maria Teresa Pellecchia1 1Departm...
Background: Patients with Parkinson’s disease (PD) have variable rates of progression. More accurate...
BackgroundParkinson’s disease (PD) is the second‐most common neurodegenerative disorder after Alzhei...
Parkinson's disease (PD) is a neurodegenerative disorder whose aetiology remains unclear: degenerati...
Parkinson\u27s disease (PD) is a highly prevalent and irreversible neurodegenerative disorder that i...
Biomarkers are characteristics that can be measured as an indicator of a normal biological process, ...
Parkinson's disease is a common multisystem neurodegenerative disorder characterized by typical moto...
Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the co...
Background: Using surrogate biomarkers for disease progression as endpoints in neuroprotective clin...
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selecti...
Parkinson’s Disease (PD) is the most prevalent neurodegenerative disease following Alzheimer’s disea...
Parkinson’s disease (PD) is a progressive neurodegenerative disorder caused mainly by lack of dopami...
Parkinson’s disease (PD) is a common, heterogeneous syndrome diagnosed clinically by the presence of...
peer-reviewedParkinson’s disease (PD) is the second-leading cause of dementia and is characterized b...
The need for an early and differential diagnosis of Parkinson's disease (PD) is undoubtedly one of t...
Marina Picillo,1 Marcello Moccia,2 Emanuele Spina,2 Paolo Barone,1 Maria Teresa Pellecchia1 1Departm...
Background: Patients with Parkinson’s disease (PD) have variable rates of progression. More accurate...
BackgroundParkinson’s disease (PD) is the second‐most common neurodegenerative disorder after Alzhei...